Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesImatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter
Oncology (Karger), 09/10/09
Adenis A et al. – Whereas 10 years ago no effective systemic therapy was available for gastrointestinal stromal tumors, the introduction of imatinib into clinical practice has dramatically improved the outcome of advanced disease, through favorable impact on disease–free survival for some patients with a localized and resectable tumor.
Related Articles
Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09
Relevance Score: 95%
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09
Relevance Score: 91%
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09
Relevance Score: 88%
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, 10/07/09
Relevance Score: 87%
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09
Relevance Score: 87%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/11/09
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet - Early Online Publication, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor